Celsion Co. (NASDAQ:CLSN) Director Frederick J. Fritz bought 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were acquired at an average price of $1.39 per share, with a total value of $13,900.00. Following the transaction, the director now directly owns 51,491 shares of the company’s stock, valued at approximately $71,572.49. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
NASDAQ:CLSN opened at $1.44 on Friday. The company has a current ratio of 3.47, a quick ratio of 3.47 and a debt-to-equity ratio of 0.58. Celsion Co. has a 12-month low of $1.19 and a 12-month high of $2.63. The stock has a 50-day moving average price of $1.67 and a 200 day moving average price of $1.83. The stock has a market capitalization of $31.65 million, a P/E ratio of -2.12 and a beta of 1.93.
Celsion (NASDAQ:CLSN) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. Celsion had a negative return on equity of 53.40% and a negative net margin of 1,489.20%. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.13 million. On average, research analysts predict that Celsion Co. will post -1.09 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Celsion stock. Vanguard Group Inc. boosted its position in shares of Celsion Co. (NASDAQ:CLSN) by 43.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 704,651 shares of the biotechnology company’s stock after buying an additional 211,779 shares during the period. Vanguard Group Inc. owned approximately 3.44% of Celsion worth $1,282,000 as of its most recent SEC filing. 5.50% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms recently issued reports on CLSN. Zacks Investment Research cut Celsion from a “hold” rating to a “sell” rating in a research report on Wednesday, October 16th. Brookline Capital Management reiterated a “buy” rating on shares of Celsion in a research report on Thursday, July 25th. Finally, ValuEngine upgraded Celsion from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
See Also: How to identify percentage decliners
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.